Featured News

Expanding In-Vitro Diagnostics and Research & Development Capabilities

To Support Current Clients and Growing Market Needs, MRIGlobal Headquarters Creates In-vitro Diagnostics Center of Excellence. 
MRIGlobal is proudly celebrating its 75th anniversary in 2019.  As a part of this celebration, MRIGlobal is establishing an In-vitro Diagnostics Center of Excellence at its headquarters in Kansas City, Missouri.

The center will expand MRIGlobal’s In-vitro Diagnostics and Research and Development capabilities.

It will occupy newly renovated, state-of-the-art laboratories designed specifically to support all phases of in-vitro diagnostic product development, including College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratories.

Why the in-vitro center is needed

“The demand for MRIGlobal’s scientific expertise in in-vitro diagnostics research continues to grow,” said Thomas Sack, Ph.D., MRIGlobal President and Chief Executive Officer. “With this initiative, our experts in infectious disease, medical countermeasures, global health engagement, and in-vitro diagnostics will be better prepared to address growing global needs at the intersection of national security and world health.”

“The addition of in-vitro diagnostics capabilities positions our organization to provide our customers with a wealth of capabilities to solve their problems,” said Bob Conklin, MRIGlobal Vice President of Research Operations. “We are excited about this larger presence in Kansas City. It will foster greater collaboration among the region’s rich ecosystem of universities, clinical research, medical centers, and growing CRO community. This expansion of capabilities is beneficial to MRIGlobal and the greater Kansas City region.” 

“We are excited about the opportunity to expand our in-vitro diagnostics and research and development capabilities,”said Joseph Bogan, Ph.D., MRIGlobal Director of Global Health Surveillance andDiagnostics. “The establishment of the Center will allow MRIGlobal to continue to provide high quality services to our current clients, expand our services to a growing in-vitro diagnostics market, and foster synergies through collaboration across MRIGlobal.”

To learn more about our in-vitro diagnostic capabilities, visit here.